“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer - Episode 2

HER2-targeted Therapy: Routes of Administration

September 23, 2020
Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology

,
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

,
Susan Hays, ANP, Washington University Siteman Cancer Center

,
Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management ofHER2+breast cancer and examining the potential use of at-home administration.

Data from the following clinical trial are discussed:

  • Patient preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab and trastuzumab in pts with HER2-positive early breast cancer: Interim analysis of the open-label, randomized crossover PHranceSCa study. (O’Shaughnessy J et al. 2020 ESMO annual meeting. Abstract 80O.)

x